Robert Michael Dudley is CEO at Transcode Therapeutics, Inc. (RNAZ). They have made 5 open-market trades across 1 company since 2022, most recently 2023-09-28.
CIK 0001854161
5 open-market purchases totalling $282K since 2022, never a sale. Across 5 scored buys the stock is down 60.8% at ninety days, and 63.5 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| RNAZ | 180,262 | $312K |
Shares reported on the most recent Form 4, priced at the 2023-10-02 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 0% |
| Avg Move | -11.8% | -15.5% | -60.8% |
| Alpha | -10.4% | -14.8% | -63.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RNAZ | BUY | 2023-09-28 | 2023-10-02 | $0.51 | $50K | -11.0% | -25.6% | -67.7% |
| RNAZ | BUY | 2023-06-20 | 2023-06-22 | $2.61 | $49K | -6.8% | -6.8% | -73.5% |
| RNAZ | BUY | 2023-06-09 | 2023-06-14 | $2.76 | $105K | -6.9% | -8.0% | -66.3% |
| RNAZ | BUY | 2022-09-14 | 2022-09-16 | $1.15 | $23K | -9.8% | -4.9% | -63.4% |
| RNAZ | BUY | 2022-05-27 | 2022-06-01 | $1.84 | $55K | -24.7% | -32.3% | -32.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.